In addition, a recent legal win for Enbrel patents should keep biosimilar rivals at bay for the blockbuster drug for the rest of the decade.Earlier this year, Gilead acquired cancer-focused biotech Forty Seven and established a 10-year partnership to develop cancer immunotherapies with Arcus Biosciences.